| [1] |
中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1): 24-56.
|
| [2] |
刘力生. 高血压慢性病管理与展望[J]. 中华高血压杂志, 2019, 27(3):209-210.
|
| [3] |
中华医学会心血管病学分会, 中国康复医学会心脏预防与康复专业委员会, 中国老年学和老年医学会心脏专业委员会, 等. 中国心血管病一级预防指南[J]. 中华心血管病杂志, 2020, 48(12):1000-1038.doi:10.3760/cma.j.cn112148-20201009-00796.
|
| [4] |
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants[J]. Lancet, 2021, 398(10304):957-980.doi: 10.1016/S0140-6736(21)01330-1. Epub 2021 Aug 24.
|
| [5] |
Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice[J]. Eur Heart J, 2021, 42(34):3227-3337.doi: 10.1093/eurheartj/ehab484.
pmid: 34458905
|
| [6] |
中国高血压防治指南修订委员会, 高血压联盟(中国), 中国医疗保健国际交流促进会高血压分会, 等. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志, 2024, 32(7):603-700.doi:10.16439/j.issn.1673-7245.2024.07.002.
|
| [7] |
Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries[J]. Circulation, 2016, 134(6):441-450.doi: 10.1161/CIRCULATIONAHA.115.018912.
pmid: 27502908
|
| [8] |
Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure[J]. Hypertension, 2003, 42(6):1206-1252.doi: 10.1161/01.HYP.0000107251.49515.c2.Epub 2003 Dec 1.
pmid: 14656957
|
| [9] |
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2013, 34(28):2159-2219.doi: 10.1093/eurheartj/eht151. Epub 2013 Jun 14.
pmid: 23771844
|
| [10] |
Ahmad FS, Ning H, Rich JD, et al. Hypertension stage, time to revise, and cardiovascular outcomes[J]. J Am Coll Cardiol, 2020, 75(9):1002-1012.
doi: 10.1016/S0735-1097(20)31629-6
URL
|
| [11] |
上海市医学会糖尿病专科分会, 上海市医学会内分泌专科分会. 成人糖尿病患者血压管理专家共识[J]. 上海医学, 2021, 44(01):8-18.doi:10.19842/j.cnki.issn.0253-9934.2021.01.002.
|
| [12] |
Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis[J]. Lancet, 2016, 387(10022):957-967.doi: 10.1016/S0140-6736(15)01225-8. Epub 2015 Dec 24.
|
| [13] |
Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control[J]. N Engl J Med, 2015, 373(22):2103-2116.doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9.
|
| [14] |
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators[J]. N Engl J Med, 2000, 342(3):145-153.doi: 10.1056/NEJM200001203420301.
|
| [15] |
Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: An individual participant-level data meta-analysis[J]. Lancet, 2021, 397(10285):1625-1636.doi: 10.1016/S0140-6736(21)01069-2.
pmid: 33933205
|
| [16] |
王增武, 王圣, 冯彩霞, 等. 中国卒中患者高血压管理专家共识[J]. 中国卒中杂志, 2024, 19(6):672-698.
|